Familial multiple lipomatosis

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:199276OMIM:151900E88.2
Who is this for?
Show terms as
1Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Familial multiple lipomatosis (FML), also known as hereditary multiple lipomatosis, is a rare genetic condition characterized by the development of numerous benign fatty tumors (lipomas) distributed symmetrically across the body. These lipomas are soft, painless, encapsulated subcutaneous masses composed of mature adipose (fat) tissue. They most commonly appear on the trunk, extremities (particularly the forearms and thighs), and occasionally on the neck and shoulders. The condition primarily affects the integumentary system and subcutaneous tissue, though the lipomas generally do not involve deeper structures such as muscles or internal organs. Familial multiple lipomatosis typically manifests in adulthood, often between the third and fifth decades of life. The lipomas tend to increase in number and size over time. While the condition is generally considered benign and the lipomas rarely undergo malignant transformation, they can cause cosmetic concerns and occasionally local discomfort or pain due to compression of nearby nerves. Unlike Dercum disease (adiposis dolorosa), the lipomas in FML are usually painless, and unlike multiple symmetric lipomatosis (Madelung disease), FML lipomas are well-encapsulated and more widely distributed rather than forming diffuse, unencapsulated fatty masses around the neck and shoulders. There is no curative treatment for familial multiple lipomatosis. Management is primarily symptomatic and includes surgical excision or liposuction of individual lipomas that cause pain, functional impairment, or significant cosmetic distress. However, recurrence after removal is possible, and new lipomas may continue to develop. Genetic counseling is recommended for affected families. The exact genetic basis remains incompletely characterized, though some studies have suggested linkage to chromosome 12q13-q15, a region containing the HMGA2 gene involved in adipocyte biology.

Clinical phenotype terms— hover any for plain English:

Subcutaneous lipomaHP:0001031Cutaneous angiolipomasHP:0006773OverweightHP:0025502Painful subcutaneous lipomasHP:0007596Subcutaneous calcificationHP:0007618
Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Familial multiple lipomatosis.

View clinical trials →

No actively recruiting trials found for Familial multiple lipomatosis at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Familial multiple lipomatosis community →

Specialists

1 foundView all specialists →
LS
Laurent Servais
Specialist
PI on 1 active trial28 Familial multiple lipomatosis publications

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Familial multiple lipomatosis.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Familial multiple lipomatosisForum →

No community posts yet. Be the first to share your experience with Familial multiple lipomatosis.

Start the conversation →

Latest news about Familial multiple lipomatosis

No recent news articles for Familial multiple lipomatosis.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Familial multiple lipomatosis

What is Familial multiple lipomatosis?

Familial multiple lipomatosis (FML), also known as hereditary multiple lipomatosis, is a rare genetic condition characterized by the development of numerous benign fatty tumors (lipomas) distributed symmetrically across the body. These lipomas are soft, painless, encapsulated subcutaneous masses composed of mature adipose (fat) tissue. They most commonly appear on the trunk, extremities (particularly the forearms and thighs), and occasionally on the neck and shoulders. The condition primarily affects the integumentary system and subcutaneous tissue, though the lipomas generally do not involve

How is Familial multiple lipomatosis inherited?

Familial multiple lipomatosis follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Familial multiple lipomatosis typically begin?

Typical onset of Familial multiple lipomatosis is adult. Age of onset can vary across affected individuals.

Which specialists treat Familial multiple lipomatosis?

1 specialists and care centers treating Familial multiple lipomatosis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.